Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

B-cell receptor (BCR) signaling is aberrantly activated in chronic lymphocytic leukemia (CLL). Bruton tyrosine kinase (BTK) is essential to BCR signaling and in knockout mouse models its mutation has a relatively B cell–specific phenotype. Herein, we demonstrate that BTK protein and mRNA are signifi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Herman, Sarah E. M., Gordon, Amber L., Hertlein, Erin, Ramanunni, Asha, Zhang, Xiaoli, Jaglowski, Samantha, Flynn, Joseph, Jones, Jeffrey, Blum, Kristie A., Buggy, Joseph J., Hamdy, Ahmed, Johnson, Amy J., Byrd, John C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2011
Gaiak:
Lymphoid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3122947/
https://ncbi.nlm.nih.gov/pubmed/21422473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-01-328484
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak